BiotechTube

Ceftolozane/tazobactam + Meropenem

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthcare-Associated Pneumonia

Conditions

Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases

Trial Timeline

Sep 2, 2014 → Jun 6, 2018

NCT ID
NCT02070757

About Ceftolozane/tazobactam + Meropenem

Ceftolozane/tazobactam + Meropenem is a phase 3 stage product being developed by Merck for Healthcare-Associated Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02070757. Target conditions include Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases.

What happened to similar drugs?

0 of 2 similar drugs in Healthcare-Associated Pneumonia were approved

Approved (0) Terminated (0) Active (2)
🔄Cefiderocol + Best Available TherapyShionogiPhase 3
🔄Cefiderocol + Meropenem + LinezolidShionogiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03230838Phase 2Completed
NCT02070757Phase 3Completed

Competing Products

2 competing products in Healthcare-Associated Pneumonia

See all competitors
ProductCompanyStageHype Score
Cefiderocol + Best Available TherapyShionogiPhase 3
40
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
40